Revenio Group Oyj

OTCPK:REVX.F Stock Report

Market Cap: US$774.5m

Revenio Group Oyj Valuation

Is REVX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REVX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REVX.F ($30.8) is trading below our estimate of fair value ($39.84)

Significantly Below Fair Value: REVX.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REVX.F?

Key metric: As REVX.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REVX.F. This is calculated by dividing REVX.F's market cap by their current earnings.
What is REVX.F's PE Ratio?
PE Ratio38.7x
Earnings€19.11m
Market Cap€738.84m

Price to Earnings Ratio vs Peers

How does REVX.F's PE Ratio compare to its peers?

The above table shows the PE ratio for REVX.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.4x
IRMD IRADIMED
36.2x15.5%US$660.0m
INMD InMode
10.2x7.5%US$1.5b
TCMD Tactile Systems Technology
24.8x29.3%US$373.4m
SMLR Semler Scientific
30.3xn/aUS$430.7m
REVX.F Revenio Group Oyj
38.7x19.0%US$738.8m

Price-To-Earnings vs Peers: REVX.F is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does REVX.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.9xn/aUS$16.93m
PAVM PAVmed
0.7x-77.8%US$10.72m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
REVX.F 38.7xIndustry Avg. 36.5xNo. of Companies10PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: REVX.F is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the US Medical Equipment industry average (36.5x).

Price to Earnings Ratio vs Fair Ratio

What is REVX.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REVX.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REVX.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REVX.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$34.48
0%
4.0%US$36.85US$33.69n/a4
Nov ’25n/a
US$35.03
0%
5.2%US$37.93US$32.83n/a4
Oct ’25US$38.89
US$34.79
-10.6%
3.0%US$36.07US$33.12n/a4
Sep ’25n/a
US$34.79
0%
3.0%US$36.07US$33.12n/a4
Aug ’25n/a
US$32.99
0%
9.2%US$36.98US$29.70n/a4
Jul ’25n/a
US$31.27
0%
7.5%US$34.44US$28.20n/a4
Jun ’25n/a
US$31.37
0%
6.3%US$34.23US$29.20n/a4
May ’25n/a
US$31.37
0%
6.3%US$34.23US$29.20n/a4
Apr ’25n/a
US$31.64
0%
5.9%US$34.84US$29.72n/a5
Mar ’25n/a
US$30.03
0%
5.7%US$32.32US$27.48n/a4
Feb ’25n/a
US$27.75
0%
6.9%US$30.47US$25.03n/a4
Jan ’25n/a
US$26.83
0%
8.4%US$30.23US$24.73n/a4
Dec ’24n/a
US$26.77
0%
8.4%US$30.47US$24.92n/a4
Nov ’24n/a
US$26.71
0%
7.2%US$29.59US$24.30n/a4
Oct ’24n/a
US$28.98
0%
5.1%US$31.54US$27.84US$38.894
Sep ’24n/a
US$28.98
0%
5.1%US$31.54US$27.84n/a4
Aug ’24n/a
US$42.97
0%
7.4%US$46.68US$38.44n/a4
Jul ’24US$34.80
US$42.38
+21.8%
6.4%US$45.74US$38.74n/a4
Jun ’24n/a
US$43.85
0%
4.8%US$46.78US$41.83n/a3
May ’24n/a
US$44.08
0%
5.4%US$47.38US$41.87n/a3
Apr ’24n/a
US$43.10
0%
5.1%US$45.95US$40.61n/a3
Mar ’24n/a
US$43.10
0%
5.1%US$45.95US$40.61n/a3
Feb ’24n/a
US$44.99
0%
4.2%US$47.69US$43.65n/a3
Jan ’24n/a
US$41.42
0%
3.8%US$43.54US$39.86n/a3
Dec ’23n/a
US$41.42
0%
3.8%US$43.54US$39.86n/a3
Nov ’23n/a
US$41.42
0%
3.8%US$43.54US$39.86n/a3

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$92.2b

Operates as a health benefits company in the United States.

ELV

US$403.60

7D

-0.8%

1Y

-15.9%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%